- Solid top-line and normalising costs; Q2 EBITA +15% vs.
Redeye comments on Bredband2’s Q2 report which posted marginally stronger performance across the boa...
Relais Q2 adjusted EBITA of EUR 7.6m was up 3% y/y and came 2% above LSEG Data & Analytics consensus...
Dovre’s project challenges have been extended, but Sweden and Finland should offer more opportunitie...
Redeye provides an update on Scandinavian ChemoTech following the Q2 2025 report.
Redeye comments on the SEK2.2m milestone bonus payment received for a game under a work-for-hire agr...
Redeye is encouraged by the NTAP for CERAMENT G used in trauma, as it aids in the company’s early-st...
EBIT -9% vs cons, -15% vs ABGSC Order backlog +25%, organic growth +43% y-o-y We expect limited esti...
Margin upside building into H2 We cut EBITDA by 9-4% for '25e-'27e Trading at ~22x '26e EV/EBITDA F...
Alisa Bank’s H1 was slightly weaker than expected. We remain cautious on near-term development but n...
Redeye updates in Better Collective ahead of Q2-results (due 20 August after market close) where we ...
Redeye updates its view on Genovis' following a Q2 2025 report falling slightly short of our estimat...
The economic environment and end demand has not been very favourable for Aspo.
Redeye comments on Xspray’s out-licensing of certain patents covering the commercialization of a das...
The company’s adjusted EBITDA was EUR 3.1m (pre-announced) in Q2.
